LINC00887 Fosters Development of Clear Cell Renal Cell Carcinoma via Inhibiting CD8+ T Cell Immune Infiltration
暂无分享,去创建一个
Jinfeng Wu | Yongbao Wei | W. Cai | Ruochen Zhang | R. Lin | Weilie Hu | Lei Zhang
[1] L. Qin,et al. GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages , 2021, Signal Transduction and Targeted Therapy.
[2] S. Salek-Ardakani,et al. CD8+ T Cell Exhaustion in Cancer , 2021, Frontiers in Immunology.
[3] Ming-Rong Zhang,et al. Off-tumor IDO1 target engagements determine the cancer-immune set point and predict the immunotherapeutic efficacy , 2021, Journal for ImmunoTherapy of Cancer.
[4] Qiang Sun,et al. SDHB Suppresses the Tumorigenesis and Development of ccRCC by Inhibiting Glycolysis , 2021, Frontiers in Oncology.
[5] Zhenlin Yang,et al. LINC00152 mediates CD8+ T-cell infiltration in gastric cancer through binding to EZH2 and regulating the CXCL9, 10/CXCR3 axis , 2021, Journal of Molecular Histology.
[6] Yang Jiang,et al. Pan-Cancer Analysis of NOS3 Identifies Its Expression and Clinical Relevance in Gastric Cancer , 2021, Frontiers in Oncology.
[7] J. Larkin,et al. Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] N. Liu,et al. LINC00887 aggravates the malignant progression of glioma via upregulating CCND1. , 2021, European review for medical and pharmacological sciences.
[9] Pei Li,et al. Linc00887 suppresses tumorigenesis of cervical cancer through regulating the miR-454-3p/FRMD6-Hippo axis , 2021, Cancer cell international.
[10] Xu Zhang,et al. DMDRMR-Mediated Regulation of m6A-Modified CDK4 by m6A Reader IGF2BP3 Drives ccRCC Progression , 2020, Cancer Research.
[11] R. Xu,et al. LncRNA‐mediated posttranslational modifications and reprogramming of energy metabolism in cancer , 2020, Cancer communications.
[12] P. Hegde,et al. Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. , 2020, Cancer cell.
[13] ping wang,et al. MiR-125b-2-3p associates with prognosis of ccRCC through promoting tumor metastasis via targeting EGR1. , 2020, American journal of translational research.
[14] Y. Wang,et al. LINC00887 regulates the proliferation of nasopharyngeal carcinoma via targeting miRNA-203b-3p to upregulate NUP205. , 2020, European review for medical and pharmacological sciences.
[15] Biao Zhang,et al. LncRNA KCNQ1OT1 sponges miR-15a to promote immune evasion and malignant progression of prostate cancer via up-regulating PD-L1 , 2020, Cancer Cell International.
[16] Hui Zhang,et al. LINC00973 is involved in cancer immune suppression through positive regulation of Siglec‐15 in clear‐cell renal cell carcinoma , 2020, Cancer science.
[17] Yanlv Ren,et al. LncRNA GATA3‐AS1 facilitates tumour progression and immune escape in triple‐negative breast cancer through destabilization of GATA3 but stabilization of PD‐L1 , 2020, Cell proliferation.
[18] Y. Zhong,et al. Serum long non‐coding RNA LINC00887 as a potential biomarker for diagnosis of renal cell carcinoma , 2020, FEBS open bio.
[19] W. Rathmell,et al. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma , 2020, Nature Communications.
[20] Yangchun Xie,et al. LncRNA NEAT1 Interacted With DNMT1 to Regulate Malignant Phenotype of Cancer Cell and Cytotoxic T Cell Infiltration via Epigenetic Inhibition of p53, cGAS, and STING in Lung Cancer , 2020, Frontiers in Genetics.
[21] Jing Ma,et al. Expression of RSK4, CD44 and MMP-9 is upregulated and positively correlated in metastatic ccRCC , 2020, Diagnostic Pathology.
[22] Zhao-yun Li,et al. lncRNA TCL6 correlates with immune cell infiltration and indicates worse survival in breast cancer , 2020, Breast Cancer.
[23] Lihui Wang,et al. LncRNA-LET inhibits cell growth of clear cell renal cell carcinoma by regulating miR-373-3p , 2019, Cancer Cell International.
[24] M. Hung,et al. Mechanisms Controlling PD-L1 Expression in Cancer. , 2019, Molecular cell.
[25] Lorenzo Marconi,et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. , 2019, European urology.
[26] Zhigui Li,et al. PD‐1/PD‐L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway , 2019, Cell proliferation.
[27] Aimin Jiang,et al. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment , 2018, Front. Immunol..
[28] Li Jiang,et al. LncRNA-MM2P Identified as a Modulator of Macrophage M2 Polarization , 2018, Cancer Immunology Research.
[29] G. Burness,et al. 50 years of comparative biochemistry: The legacy of Peter Hochachka. , 2018, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.
[30] H. Yao,et al. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death , 2018, Nature Immunology.
[31] H. Moch,et al. Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer. , 2016, European urology.
[32] Obi L. Griffith,et al. GenVisR: Genomic Visualizations in R , 2016, bioRxiv.
[33] Bin Zhang,et al. Local production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma , 2015, Oncotarget.
[34] James A. Heward,et al. Long non-coding RNAs in the regulation of the immune response , 2014, Trends in Immunology.
[35] Mark D. Robinson,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..